$1.59
+0.04 (+2.58%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where CVM is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
2 interventional · 1 with posted results
Held by 3 tracked-famous managers (RENAISSANCE TECHNOLOGIES LLC, CITADEL ADVISORS LLC, JANE STREET GROUP, LLC) · FINRA short interest 3.8 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| Efficacy and Safety Study of Leukocyte Interleukin,Injection (LI) to Treat Cancer of the Oral CavityNCT01265849results2022-08-19Overall Survival (OS)Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan: SAP main text ↗ · Statistical Analysis Plan: CS001P3 Note to File 1 ↗ · Statistical Analysis Plan: CS001P3 Note to file 2 ↗ · Statistical Analysis Plan: Note to file 3 ↗ · Statistical Analysis Plan: Note to file 4 ↗ · Statistical Analysis Plan: Note to file 5 ↗ | Phase 3 | Completed | Biological: LI · Drug: Cyclophosphamide, Indomethacin, Cisplatin · Dietary supplement: Zinc · Procedure: Surgery · Radiation: Radiotherapy | Squamous Cell Carcinoma of the Oral Cavity, Squamous Cell Carcinoma of the Soft Palate | 928 | 2020-05-15actual | 2022-08-19 |
| Study of Leukocyte Interleukin, Injection for Treatment of Perianal WartsNCT03038828Wart characterization changeNon-randomized · Open-label · Other | Phase 1 | Terminatedsponsor's stated reason: Insufficient enrollment | Biological: Leukocyte Interleukin, Injection | Perianal Warts | 8 | Jun 2018actual | 2023-09-22 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19